活化蛋白C在重症肺炎患者预后评估中的应用价值

摘要
图/表
参考文献(19)
相关文章 (3)

全文: PDF (0 KB) HTML (27 KB)
输出: BibTeX | EndNote (RIS)

摘要目的观察重症肺炎患者血清中活化蛋白C（APC）的表达水平，评判其在评估重症肺炎患者预后评估中的价值。方法选择2013年10月～2016年7月我科诊治重症肺炎患者54例，按预后分为存活组（30例）和死亡组（24例）。随机选取同期我院的非重症肺炎患者30例作为非重症肺炎组，选取同期在我院查体的健康人30例作为健康组，采用酶联免疫吸附法检测各组血清中的APC水平。结果肺炎组患者与健康人比较，肺炎组的APC水平为（330.81±72.80）ng/ml，低于健康组[（436.57±62.69）ng/ml]，差异有统计学意义（P<0.05）；重症肺炎组的 APC 水平为（296.60±58.26）ng/ml，低于非重症肺炎组[（392.38±53.52）ng/ml]，差异有统计学意义（P<0.05）；死亡组的 APC水平为（263.89±53.53）ng/ml，低于存活组[（322.75±48.34）ng/ml]，差异有统计学意义（P<0.05）。结论血清中 APC 水平与肺炎相关，APC水平反应患者疾病严重程度，且与重症肺炎预后相关，APC水平越低，患者预后越差。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	牟伟峰
	董茂萱

关键词 ：重症肺炎, 活化蛋白C, 全身性炎症反应综合征, 急性肺损伤/急性呼吸窘迫综合征, 多器官功能不全

Abstract：ObjectiveTo observe the level of serum activated protein C(APC)in patients with severe pneumonia and evaluate its value in evaluating the prognosis of patients with severe pneumonia.MethodsA total of 54 patients with severe pneumonia were selected from October 2013 to July 2016,the prognosis was divided into survival group(n=30)and death group(n=24).30 patients with non-severe pneumonia were selected randomly in the same period,as a non-severe pneumonia group.A healthy group of 30 healthy people were selected in our hospital during the same period.Using enzyme-linked immunosorbent method to detect each group APC level in the serum.ResultsThe APC level of the pneumonia group was(330.81±72.80)ng/ml,which was lower than that the healthy group[(436.57±62.69)ng/ml],and the difference was statistically significant(P<0.05).The APC level of the severe pneumonia group was(296.60±58.26)ng/ml,which was lower than that the non-severe pneumonia group [(392.38±552)ng/ml],and the difference was statistically significant(P<0.05).The APC level of the death group was(263.89±53.53)ng/ml,which was lower than that the survival group [(322.75±48.34)ng/ml],and the difference was statistically significant(P<0.05).ConclusionLevel of APC in serum is associated with pneumonia,and the level of APC reflects the severity of the disease and is related to the prognosis of severe pneumonia.The lower the APC level,the worse the prognosis of the patients.

Key words： Severe pneumonia Activated protein C System inflammatory response syndrome Acute lung injury/Acute respiratory distress syndrome Multiple organ dysfunction syndrome

引用本文:

牟伟峰；董茂萱. 活化蛋白C在重症肺炎患者预后评估中的应用价值[J]. 中国当代医药, 2018, 25(5): 38-40.
MU Wei-feng ；DONG Mao-xuan. The application value of APC level for the prognosis assessment of patients with severe pneumonia. 中国当代医药, 2018, 25(5): 38-40.

链接本文:

http://dangdaiyiyao.com/CN/ 或 http://dangdaiyiyao.com/CN/Y2018/V25/I5/38

[1]	林大勇.降钙素原检测在重症肺炎治疗中的应用价值[J].中国当代医药，2016,23（6）：37-39.
[2]	Mayr FB，Yende S，Angus DC.Epidemiology of severe sepsis[J].Virulence，2014，5（1）：4-11.
[3]	宋志芳，郭晓红，王树云，等.糖皮质激素在重症社区获得性肺炎致急性呼吸窘迫综合征救治中的价值探讨[J].中国危重病急救医学，2003，15（11）：669-674.
[4]	谭经福，张艳顺.河源地区血清降钙素原和C反应蛋白在重症肺炎患者诊变化过程中的价值[J].当代医学，2014，20（18）:16-17.
[5]	陈德昌.全身感染：观察、假设和验证[J].中华危重病急救医学，2013，25（1）：1-2.
[6]	李亚莉，李志军，王东强，等.毛细血管渗漏综合征的治疗进展[J].中国中西医结合急救杂志，2014，21（1）：77-78.
[7]	Okajima K.SIRS and the coagulation of normality[J].Rinsho Byori，2000，48（6）：510-515.
[8]	陈淼，戴李华.全身炎症反应综合征患者凝血功能的研究[J].中国急救医学，2005，25（8）：547-549.
[9]	Tagami T，Matsui H，Fushimi K，et al.Use of recombinant human soluble thrombomodulin in patients with sepsis-induced disseminated intravascular coagulation after intestinal perforation[J].Front Med，2015， 2（479/480）：667-674.
[10]	Simmons J，Pittet JF.The coagulopathy of acute sepsis[J].Curr Opin Anaesthesiol，2015，28（2）：227-236.
[11]	Sung JY，Kim JE，Kim KS，et al.Differential expression of leukocyte receptors in disseminated intravascular coagulation：prognostic value of low protein C receptor expression[J].Thromb Res，2014，134（5）：130-1134.
[12]	Stephenson DA Toltl IJ，Beaudin S，et al.Modulation of monocyte functiong by activeed protein C，a natural anticoagulant[J].J Immunol，2006，177（4）：2115-2122.
[13]	侯超，明少菊，张旭.血清降钙素原在重症肺炎诊断中的临床价值[J].现代诊断与治疗，2013，24（12）:2791-2792.
[14]	Messaris E，Betrosian AP，Memos N，et al.Administration of human protein C improves survivalinan experimental model of sepsis[J].Crit Care Med，2010，38（1）：209-216.
[15]	Gupta A，Gerfitz B，Richardson MA，et al.Distinct functions of activated protein C differentially attenuate acute kidney injury[J].J Am Soc Nephrol，2009，20（2）：267-277.
[16]	Nagai M，Tera S，Yilmaz G，et al.Roles of inflammation and the activated protein C pathway in the brain edemaassociated with cerebral venous sinus thrombois[J].Stroke，2010，41（1）：147-152.
[17]	Hoffmann JN，Vollmar B，Laschke MW，et al.Microhemodynamic and cellular mechanisms of activated protein C action during endotoxemia[J].Crit Care Med，2004，32（4）：1011-1017.
[19]	Toussaint S，Gerlach H.Activated protein C for sepsis[J].N Engl J Med，2009，361（27）：2646-2652.
[18]	Bernard GR.Magolis BD，Shanies HM，et al.Extended evaluation of recombinant human activated protein C united states trial（ENHANCE US）：a single-arm，phase 3B， mlticenter study of drotrecogin alfa （activated） in severe sepsis[J].Chest，2004，125（6）：2206-22l6.